Literature DB >> 18181237

A semi-structured interview to assess visual hallucinations in older people.

Urs Peter Mosimann1, Daniel Collerton, Robert Dudley, Thomas Daniel Meyer, Gemma Graham, Jennifer Louise Dean, Daniel Bearn, Alison Killen, Lucy Dickinson, Mike Patrick Clarke, Ian Grant McKeith.   

Abstract

OBJECTIVE: Visual hallucinations are under-reported by patients and are often undiscovered by health professionals. There is no gold standard available to assess hallucinations. Our objective was to develop a reliable, valid, semi-structured interview for identifying and assessing visual hallucinations in older people with eye disease and cognitive impairment.
METHODS: We piloted the North-East Visual Hallucinations Interview (NEVHI) in 80 older people with visual and/or cognitive impairment (patient group) and 34 older people without known risks of hallucinations (control group). The informants of 11 patients were interviewed separately. We established face validity, content validity, criterion validity, inter-rater agreement and the internal consistency of the NEVHI, and assessed the factor structure for questions evaluating emotions, cognitions, and behaviours associated with hallucinations.
RESULTS: Recurrent visual hallucinations were common in the patient group (68.8%) and absent in controls (0%). The criterion, face and content validities were good and the internal consistency of screening questions for hallucinations was high (Cronbach alpha: 0.71). The inter-rater agreements for simple and complex hallucinations were good (Kappa 0.72 and 0.83, respectively). Four factors associated with experiencing hallucinations (perceived control, pleasantness, distress and awareness) were identified and explained a total variance of 73%. Informants gave more 'don't know answers' than patients throughout the interview (p = 0.008), especially to questions evaluating cognitions and emotions associated with hallucinations (p = 0.02).
CONCLUSIONS: NEVHI is a comprehensive assessment tool, helpful to identify the presence of visual hallucinations and to quantify cognitions, emotions and behaviours associated with hallucinations.

Entities:  

Mesh:

Year:  2008        PMID: 18181237     DOI: 10.1002/gps.1965

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  31 in total

1.  Quetiapine in the treatment of psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Mike Samuel; Anthony David
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

2.  Advances in the treatment of visual hallucinations in neurodegenerative diseases.

Authors:  Daniel Collerton; John-Paul Taylor
Journal:  Future Neurol       Date:  2013-07

Review 3.  New evidence on the management of Lewy body dementia.

Authors:  John-Paul Taylor; Ian G McKeith; David J Burn; Brad F Boeve; Daniel Weintraub; Claire Bamford; Louise M Allan; Alan J Thomas; John T O'Brien
Journal:  Lancet Neurol       Date:  2019-09-10       Impact factor: 44.182

4.  Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Authors:  Kelsey A Holiday; Eva Pirogovsky-Turk; Vanessa L Malcarne; J Vincent Filoteo; Irene Litvan; Stephanie L Lessig; David Song; Dawn M Schiehser
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 5.  [The eye as a window to the pathophysiology in Parkinson's syndromes].

Authors:  J Kassubek; A Danek; K Del Tredici-Braak; M W Greenlee; E H Pinkhardt
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

Review 6.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 7.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

8.  Increasing Contrast Improves Object Perception in Parkinson's Disease with Visual Hallucinations.

Authors:  Mirella Díaz-Santos; Zachary A Monge; Robert D Salazar; Grover C Gilmore; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Mov Disord Clin Pract       Date:  2020-11-17

9.  Benefit of psychiatric evaluation on anxiety in patients with Charles Bonnet syndrome.

Authors:  Birgit Doeller; Martin Kratochwil; Lena Sifari; Nino Hirnschall; Oliver Findl
Journal:  BMJ Open Ophthalmol       Date:  2021-02-23

10.  An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB).

Authors:  Frederick M Lang; Daniel Y Kwon; Dag Aarsland; Brad Boeve; Babak Tousi; Mark Harnett; Yi Mo; Marwan Noel Sabbagh
Journal:  Alzheimers Dement (N Y)       Date:  2021-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.